Voyager Therapeutics Inc  

(Public, NASDAQ:VYGR)   Watch this stock  
Find more results for VYGR
18.64
+0.12 (0.65%)
Real-time:   2:29PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 18.42 - 18.80
52 week 8.10 - 25.99
Open 18.53
Vol / Avg. 168,226.00/360,532.00
Mkt cap 502.37M
P/E     -
Div/yield     -
EPS -2.84
Shares 26.95M
Beta     -
Inst. own 78%
Mar 13, 2018
Q4 2017 Voyager Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Nov 29, 2017
Voyager Therapeutics Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference
Nov 28, 2017
Voyager Therapeutics Inc at Piper Jaffray Healthcare Conference
Nov 16, 2017
Voyager Therapeutics R&D Day - Webcast
Nov 15, 2017
Voyager Therapeutics Inc at Stifel Healthcare Conference
Nov 2, 2017
Q3 2017 Voyager Therapeutics Inc Earnings Call - Webcast
Oct 30, 2017
Voyager Therapeutics, Inc. - Special Call - Webcast
Oct 30, 2017
Q3 2017 Voyager Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -2033.62% -282.65%
Operating margin -2034.41% -290.43%
EBITD margin - -286.13%
Return on average assets -62.57% -19.18%
Return on average equity -98.31% -26.36%
Employees 77 -
CDP Score - -

Address

75 Sidney St
CAMBRIDGE, MA 02139-4134
United States - Map
+1-857-2595340 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

Officers and directors

Mark J. Levin Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Steven M. Paul M.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Jane V Henderson Chief Financial Officer, Senior Vice President
Age: 50
Bio & Compensation  - Reuters
Matthew P. Ottmer Chief Operating Officer
Age: 46
Bio & Compensation  - Reuters
Robert G. Pietrusko Senior Vice President - Regulatory Affairs
Age: 69
Bio & Compensation  - Reuters
Dinah Sah Ph.D. Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Kathleen Hayes Vice President - Human Resources
Age: 53
Bio & Compensation  - Reuters
John J. Connelly Vice President - Program and Alliance Management
Age: 47
Bio & Compensation  - Reuters
Bernard Ravina M.D. Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Glenn F. Pierce M.D. Ph.D. Director
Age: 61
Bio & Compensation  - Reuters